PCRX Pacira BioSciences Inc

Price (delayed)

$27.81

Market cap

$1.29B

P/E Ratio

198.64

Dividend/share

N/A

EPS

$0.14

Enterprise value

$1.78B

Pacira BioSciences, Inc.is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. The company's long-acting local ...

Highlights
Pacira BioSciences's debt has decreased by 28% YoY and by 4.9% from the previous quarter
The company's quick ratio rose by 21% QoQ and by 11% YoY
The company's gross margin fell by 4% YoY but it rose by 2.2% QoQ
Pacira BioSciences's EPS has shrunk by 69% YoY
The company's net income has shrunk by 67% YoY

Key stats

What are the main financial stats of PCRX
Market
Shares outstanding
46.44M
Market cap
$1.29B
Enterprise value
$1.78B
Valuations
Price to book (P/B)
1.55
Price to sales (P/S)
1.94
EV/EBIT
47.07
EV/EBITDA
14.22
EV/Sales
2.68
Earnings
Revenue
$665.69M
EBIT
$37.87M
EBITDA
$125.37M
Free cash flow
$130.25M
Per share
EPS
$0.14
Free cash flow per share
$2.81
Book value per share
$17.91
Revenue per share
$14.34
TBVPS
$18.82
Balance sheet
Total assets
$1.53B
Total liabilities
$702.91M
Debt
$590.3M
Equity
$831.55M
Working capital
$353.59M
Liquidity
Debt to equity
0.71
Current ratio
4.78
Quick ratio
3.55
Net debt/EBITDA
3.92
Margins
EBITDA margin
18.8%
Gross margin
70.1%
Net margin
1%
Operating margin
6.7%
Efficiency
Return on assets
0.4%
Return on equity
0.9%
Return on invested capital
2.8%
Return on capital employed
2.6%
Return on sales
5.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PCRX stock price

How has the Pacira BioSciences stock price performed over time
Intraday
1.94%
1 week
3.34%
1 month
-1.77%
1 year
-41.12%
YTD
-27.97%
QTD
-9.35%

Financial performance

How have Pacira BioSciences's revenue and profit performed over time
Revenue
$665.69M
Gross profit
$466.8M
Operating income
$44.61M
Net income
$6.98M
Gross margin
70.1%
Net margin
1%
Pacira BioSciences's net margin has plunged by 69% YoY
The company's net income has shrunk by 67% YoY
PCRX's operating margin is down by 41% YoY and by 7% QoQ
The company's operating income fell by 40% YoY and by 7% QoQ

Growth

What is Pacira BioSciences's growth rate over time

Valuation

What is Pacira BioSciences stock price valuation
P/E
198.64
P/B
1.55
P/S
1.94
EV/EBIT
47.07
EV/EBITDA
14.22
EV/Sales
2.68
Pacira BioSciences's EPS has shrunk by 69% YoY
PCRX's P/B is 61% below its 5-year quarterly average of 4.0 and 30% below its last 4 quarters average of 2.2
The equity has increased by 8% year-on-year and by 2.9% since the previous quarter
The price to sales (P/S) is 57% lower than the 5-year quarterly average of 4.5 and 25% lower than the last 4 quarters average of 2.6

Efficiency

How efficient is Pacira BioSciences business performance
PCRX's ROE has dropped by 68% year-on-year
Pacira BioSciences's ROA has plunged by 64% YoY
Pacira BioSciences's return on sales has decreased by 42% YoY but it has increased by 30% QoQ
Pacira BioSciences's ROIC has increased by 33% from the previous quarter but it has decreased by 33% YoY

Dividends

What is PCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PCRX.

Financial health

How did Pacira BioSciences financials performed over time
The total assets is 118% greater than the total liabilities
PCRX's total liabilities is down by 27% YoY and by 4.3% QoQ
The current ratio has grown by 21% from the previous quarter and by 18% YoY
Pacira BioSciences's debt is 29% less than its equity
Pacira BioSciences's debt to equity has decreased by 34% YoY and by 8% from the previous quarter
Pacira BioSciences's debt has decreased by 28% YoY and by 4.9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.